BRIEF-Neurocrine says INGREZZA NDA for treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA

[ad_1]

Oct 11 Neurocrine Biosciences Inc :

* Neurocrine announces INGREZZA (valbenazine) new drug
application for the treatment of tardive dyskinesia has been
accepted for priority review by U.S. FDA


* Neurocrine Biosciences Inc- INGREZZA application has been
given a prescription drug user fee act (PDUFA) target action
date of April 11, 2017

Source text for Eikon:
Further company coverage:

[ad_2]

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *